CJC-1295 + Ipamorelin
CJC-1295 + Ipamorelin is supplied lyophilized at the stated quantity per vial, sealed under nitrogen. Purity ≥99% (HPLC). Each lot is released with a Certificate of Analysis. For laboratory research use only.
CJC-1295 + Ipamorelin
Background
This research preparation pairs CJC-1295, a long-acting GHRH analog, with ipamorelin, a selective growth-hormone secretagogue (GHS-R agonist). The combination is studied on the rationale that the two act on distinct receptors, GHRH and ghrelin, that converge on pituitary somatotrophs to amplify pulsatile growth-hormone release.
The original CJC-1295 trials demonstrated sustained elevation of GH and IGF-1 with preserved pulsatility in healthy adults, while ipamorelin was characterized as the first selective GHS without significant cortisol or prolactin elevation. Combination-specific clinical data are limited; see the individual component entries.
Selected literature
- Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
- Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295. Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-4797.
References are provided for scientific context only. Citation does not imply endorsement of any use, nor a claim of safety or efficacy. Findings frequently derive from in-vitro or animal models.
Trademarks & attribution
CJC-1295 (DAC:GRF) originated at ConjuChem Biotechnologies and ipamorelin (NNC 26-0161) from Novo Nordisk research; neither has an approved trademarked drug product. Catalyst Research Labs is not affiliated with these organizations. Supplied as reference material only.
